Skip to main content
GutCited

Lactobacillus reuteri para Bloating and Intestinal Gas

B

Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dreuteri\u0026condition\u003Dbloating\u002Dand\u002Dgas'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Conclusão

Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.

Key Study Findings

basic science
Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.
Dose: Lactobacillus reuteri E9 (dose not specified) vs: Placebo Efeito: None < 0.05
Observational Study n=65 Open-label
Incidence and Characterization of SIBO in NAFLD Patients.
Dose: None vs: None Outcome: SIBO prevalence in NAFLD patients Efeito: SIBO in 37%; post-treatment 4% remained+ None

População: Adults with NAFLD diagnosed via FibroScan

Randomized Controlled Trial n=56 15 weeks Double-blind
Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and …
Dose: 4x10^8 CFU (induction), 2x10^8 CFU (standard) vs: Placebo Outcome: Constipation symptoms and QoL (Constipaq/CSS) Efeito: None pP0.05

População: Adults with functional constipation

Other n=54 Double-blind
Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, …
Dose: None vs: Simethicone Outcome: Safety and efficacy for functional bloating Efeito: None pP0.008

População: Adults with functional bloating

Meta-Analysis n=3122
Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a …
Dose: None vs: Triple therapy alone/placebo Outcome: H. pylori eradication rate and side effects Efeito: None None

População: Children with H. pylori infection

Randomized Controlled Trial n=101 16 weeks Double-blind
Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, …
Dose: L. reuteri DSM 17938 (1e8 CFU twice daily) vs: placebo Outcome: abdominal pain severity (Wong-Baker FACES) Efeito: None None

População: Children aged 6-15 with functional abdominal pain

Key Statistics

7

Estudos

500

Participantes

Positive

B

Nota

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:
100 million - 5 billion CFU/day
infantilecolic:
100 million CFU/day (DSM 17938 strain, 5 drops)
adultgisupport:
1-5 billion CFU/day

Limite superior: Well-tolerated up to 10 billion CFU/day in clinical trials

Dosagens Estudadas em Pesquisas

Dosagem Duração Efeito N
Lactobacillus reuteri E9 (dose not specified) -- Positive --
None -- Positive 65
4x10^8 CFU (induction), 2x10^8 CFU (standard) 15 weeks Positive 56
None -- Positive 54
None -- Positive 3122
L. reuteri DSM 17938 (1e8 CFU twice daily) 16 weeks Positive 101
None 4 weeks Positive --

Melhor horário: Before meals or on empty stomach; for infants, add drops to breast milk or formula

Safety & Side Effects

Efeitos Colaterais Relatados

  • Mild gas in initial days of use
  • Occasional increased fussiness in infants during adjustment (transient)
  • Rare loose stools
  • Very rare: bacteremia in immunocompromised individuals

Interações Conhecidas

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (theoretical risk in immunocompromised patients)
  • Proton pump inhibitors (altered gastric pH may affect colonization)

Ingestão máxima tolerável: Well-tolerated up to 10 billion CFU/day in clinical trials

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Lactobacillus reuteri help with Bloating and Intestinal Gas?
Based on 7 studies with 500 participants, there is moderate evidence from clinical studies that Lactobacillus reuteri may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).
How much Lactobacillus reuteri should I take for Bloating and Intestinal Gas?
Studies have used various dosages. A commonly studied range is 100 million - 5 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus reuteri?
Reported side effects may include Mild gas in initial days of use, Occasional increased fussiness in infants during adjustment (transient), Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus reuteri and Bloating and Intestinal Gas?
We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.

Related Evidence

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.